
10 Predictions for 2024, in Memory of Byron Wien
JPM’s Cembalest gives prophecy a try in a tribute to the late market sage.
JPM’s Cembalest gives prophecy a try in a tribute to the late market sage.
J.P. Morgan strategist Jared Gross sketches out how small life sciences firms are now well-placed due to higher federal research funding and a more receptive FDA.
The union says its pension fund’s mandatory vaccine policy violates collective bargaining agreements.
Recovery stocks are the place to be, says hedge fund chief, in contrast to his jeremiads of 2020.
Amazon, Microsoft, and the gang are posting better returns and will keep on rising, says Barclays.
The former head of CPPIB finished up his final day at the pension fund last week.
Strong equity markets helped index outperform benchmark 60/40 index.
The S&P 500’s happy days are numbered, with investors blind to Washington overreach, says Michael Hartnett.